To install click the Add extension button. That's it.

The source code for the WIKI 2 extension is being checked by specialists of the Mozilla Foundation, Google, and Apple. You could also do it yourself at any point in time.

4,5
Kelly Slayton
Congratulations on this excellent venture… what a great idea!
Alexander Grigorievskiy
I use WIKI 2 every day and almost forgot how the original Wikipedia looks like.
Live Statistics
English Articles
Improved in 24 Hours
Added in 24 Hours
What we do. Every page goes through several hundred of perfecting techniques; in live mode. Quite the same Wikipedia. Just better.
.
Leo
Newton
Brights
Milds

From Wikipedia, the free encyclopedia

Huprine X
Identifiers
  • (1S)-7-chloro-15-ethyl-10-azatetracyclo[11.3.1.02,11.04,9]heptadeca-2,4(9),5,7,10,14-hexaen-3-amine
PubChem CID
DrugBank
ChemSpider
ChEMBL
Chemical and physical data
FormulaC18H19ClN2
Molar mass298.81 g·mol−1
3D model (JSmol)
  • CCC1=CC2CC(C1)C3=C(C4=C(C=C(C=C4)Cl)N=C3C2)N
  • InChI=1S/C18H19ClN2/c1-2-10-5-11-7-12(6-10)17-16(8-11)21-15-9-13(19)3-4-14(15)18(17)20/h3-5,9,11-12H,2,6-8H2,1H3,(H2,20,21)
  • Key:QTPHSDHUHXUYFE-UHFFFAOYSA-N

Huprine X is a synthetic cholinergic compound developed as a hybrid between the natural product Huperzine A and the synthetic drug tacrine. It is one of the most potent reversible inhibitors of acetylcholinesterase known, with a binding affinity of 0.026nM,[1] as well as showing direct agonist activity at both nicotinic and muscarinic acetylcholine receptors.[2][3] In animal studies it has nootropic and neuroprotective effects, and is used in research into Alzheimer's disease,[4][5][6][7] and although huprine X itself has not been researched for medical use in humans, a large family of related derivatives have been developed.[8][9][10]

YouTube Encyclopedic

  • 1/1
    Views:
    2 177
  • BNGO potential to REPLACE Traditional Cytogenetic Methods! BNGO stock at AACR 2021 - BNGO updates

Transcription

References

  1. ^ Camps P, Cusack B, Mallender WD, El Achab RE, Morral J, Muñoz-Torrero D, Rosenberry TL (February 2000). "Huprine X is a novel high-affinity inhibitor of acetylcholinesterase that is of interest for treatment of Alzheimer's disease". Molecular Pharmacology. 57 (2): 409–17. PMID 10648652.
  2. ^ Roman S, Vivas NM, Badia A, Clos MV (June 2002). "Interaction of a new potent anticholinesterasic compound (+/-)huprine X with muscarinic receptors in rat brain". Neuroscience Letters. 325 (2): 103–6. doi:10.1016/s0304-3940(02)00245-8. PMID 12044632. S2CID 30405842.
  3. ^ Roman S, Badia A, Camps P, Clos MV (January 2004). "Potentiation effects of (+/-)huprine X, a new acetylcholinesterase inhibitor, on nicotinic receptors in rat cortical synaptosomes". Neuropharmacology. 46 (1): 95–102. doi:10.1016/j.neuropharm.2003.08.005. PMID 14654101. S2CID 19189750.
  4. ^ Ratia M, Giménez-Llort L, Camps P, Muñoz-Torrero D, Clos MV, Badia A (June 2010). "Behavioural effects and regulation of PKCalpha and MAPK by huprine X in middle aged mice". Pharmacology, Biochemistry, and Behavior. 95 (4): 485–93. doi:10.1016/j.pbb.2010.03.013. PMID 20363245. S2CID 34525530.
  5. ^ Ratia M, Giménez-Llort L, Camps P, Muñoz-Torrero D, Pérez B, Clos MV, Badia A (2013). "Huprine X and huperzine A improve cognition and regulate some neurochemical processes related with Alzheimer's disease in triple transgenic mice (3xTg-AD)". Neuro-Degenerative Diseases. 11 (3): 129–40. doi:10.1159/000336427. PMID 22626981. S2CID 46024586.
  6. ^ Giménez-Llort L, Ratia M, Pérez B, Camps P, Muñoz-Torrero D, Badia A, Clos MV (April 2017). "Behavioural effects of novel multitarget anticholinesterasic derivatives in Alzheimer's disease". Behavioural Pharmacology. 28 (2 and 3-Spec Issue): 124–131. doi:10.1097/FBP.0000000000000292. PMID 28125507.
  7. ^ Relat J, Pérez B, Camps P, Muñoz-Torrero D, Badia A, Victòria Clos M (January 2018). "Huprine X Attenuates The Neurotoxicity Induced by Kainic Acid, Especially Brain Inflammation". Basic & Clinical Pharmacology & Toxicology. 122 (1): 94–103. doi:10.1111/bcpt.12852. PMID 28724203.
  8. ^ Ronco C, Sorin G, Nachon F, Foucault R, Jean L, Romieu A, Renard PY (July 2009). "Synthesis and structure-activity relationship of Huprine derivatives as human acetylcholinesterase inhibitors". Bioorganic & Medicinal Chemistry. 17 (13): 4523–36. doi:10.1016/j.bmc.2009.05.005. PMID 19473849.
  9. ^ Ronco C, Foucault R, Gillon E, Bohn P, Nachon F, Jean L, Renard PY (May 2011). "New huprine derivatives functionalized at position 9 as highly potent acetylcholinesterase inhibitors". ChemMedChem. 6 (5): 876–88. doi:10.1002/cmdc.201000523. PMID 21344648. S2CID 10893910.
  10. ^ Galdeano C, Viayna E, Sola I, Formosa X, Camps P, Badia A, et al. (January 2012). "Huprine-tacrine heterodimers as anti-amyloidogenic compounds of potential interest against Alzheimer's and prion diseases". Journal of Medicinal Chemistry. 55 (2): 661–9. doi:10.1021/jm200840c. PMID 22185619.
This page was last edited on 24 February 2024, at 02:47
Basis of this page is in Wikipedia. Text is available under the CC BY-SA 3.0 Unported License. Non-text media are available under their specified licenses. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. WIKI 2 is an independent company and has no affiliation with Wikimedia Foundation.